COPENHAGEN, Denmark, June 2, 2015 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Nasdaq OMX Copenhagen A/S: ZEAL) (“Zealand”) announces that the company’s share capital has been increased by nominal DKK 51,487 divided into 51,487 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of employee warrants granted under two of the company’s warrant programs as described in the Articles of Association.
The subscription price is DKK 94.60 per share for 33,506 of the new shares of nominal DKK 1 and DKK 77.00 per share for 17,981 of the new shares of nominal DKK 1. The total proceeds to Zealand from the capital increase amounts to DKK 4,554,204.60.
Each new share of nominal DKK 1 carries one vote at Zealand’s general meetings. The new shares give rights to dividend and other rights from the time of the warrant holder’s exercise notice.
The new shares will be listed on Nasdaq Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Zealand will be nominal DKK 23,471,587 divided into 23,471,587 shares with a nominal value of DKK 1 each.
The amendment of Zealand’s Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority. The new Articles of Association are attached to this announcement and are also available on the company’s website: www.zealandpharma.com.
The content of this announcement has no impact on the company’s financial outlook for 2015.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: bmj@zealandpharma.com
Hanne Leth Hillman, Senior Vice President for Investor Relations & Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia(r) and in Phase III development as a single-injection combination with Lantus(r) (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia(r) is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015.
Zealand’s wholly-owned pipeline include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two Phase I trials as a single-use rescue pen (severe hypoglycemia) and a multiple-dose version (mild to moderate hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
Help employers find you! Check out all the jobs and post your resume.
